vs
Side-by-side financial comparison of Hershey Company (The) (HSY) and Zoetis (ZTS). Click either name above to swap in a different company.
Hershey Company (The) is the larger business by last-quarter revenue ($3.1B vs $2.3B, roughly 1.4× Zoetis). Zoetis runs the higher net margin — 26.6% vs 14.0%, a 12.6% gap on every dollar of revenue. On growth, Hershey Company (The) posted the faster year-over-year revenue change (10.6% vs 2.9%). Over the past eight quarters, Hershey Company (The)'s revenue compounded faster (22.3% CAGR vs -2.1%).
The Hershey Company, often called just Hershey or Hershey's, is an American multinational confectionery company headquartered in Hershey, Pennsylvania, which is also home to Hersheypark and Hershey's Chocolate World. The Hershey Company is one of the largest chocolate manufacturers in the world; it also manufactures baked products, such as cookies and cakes, and sells beverages like milkshakes, as well as other products. The Hershey Company was founded by Milton S. Hershey in 1894 as the Hers...
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
HSY vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.1B | $2.3B |
| Net Profit | $435.1M | $601.0M |
| Gross Margin | 39.4% | 71.7% |
| Operating Margin | 20.6% | — |
| Net Margin | 14.0% | 26.6% |
| Revenue YoY | 10.6% | 2.9% |
| Net Profit YoY | — | -0.2% |
| EPS (diluted) | — | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $3.1B | $2.3B | ||
| Q4 25 | $3.1B | $2.4B | ||
| Q3 25 | $3.2B | $2.4B | ||
| Q2 25 | $2.6B | $2.5B | ||
| Q1 25 | $2.8B | $2.2B | ||
| Q4 24 | $2.9B | $2.3B | ||
| Q3 24 | $3.0B | $2.4B | ||
| Q2 24 | $2.1B | $2.4B |
| Q1 26 | $435.1M | $601.0M | ||
| Q4 25 | $320.0M | $603.0M | ||
| Q3 25 | $276.3M | $721.0M | ||
| Q2 25 | $62.7M | $718.0M | ||
| Q1 25 | $224.2M | $631.0M | ||
| Q4 24 | $796.6M | $581.0M | ||
| Q3 24 | $446.3M | $682.0M | ||
| Q2 24 | $180.9M | $624.0M |
| Q1 26 | 39.4% | 71.7% | ||
| Q4 25 | 37.0% | 70.2% | ||
| Q3 25 | 32.6% | 71.5% | ||
| Q2 25 | 30.5% | 73.6% | ||
| Q1 25 | 33.7% | 72.0% | ||
| Q4 24 | 54.0% | 69.5% | ||
| Q3 24 | 41.3% | 70.6% | ||
| Q2 24 | 40.2% | 71.7% |
| Q1 26 | 20.6% | — | ||
| Q4 25 | 14.4% | 31.9% | ||
| Q3 25 | 13.7% | 37.0% | ||
| Q2 25 | 7.4% | 36.7% | ||
| Q1 25 | 13.2% | 36.5% | ||
| Q4 24 | 32.5% | 31.6% | ||
| Q3 24 | 20.5% | 36.6% | ||
| Q2 24 | 13.9% | 33.0% |
| Q1 26 | 14.0% | 26.6% | ||
| Q4 25 | 10.4% | 25.3% | ||
| Q3 25 | 8.7% | 30.0% | ||
| Q2 25 | 2.4% | 29.2% | ||
| Q1 25 | 8.0% | 28.4% | ||
| Q4 24 | 27.6% | 25.1% | ||
| Q3 24 | 14.9% | 28.6% | ||
| Q2 24 | 8.7% | 26.4% |
| Q1 26 | — | $1.42 | ||
| Q4 25 | — | $1.37 | ||
| Q3 25 | — | $1.63 | ||
| Q2 25 | — | $1.61 | ||
| Q1 25 | — | $1.41 | ||
| Q4 24 | — | $1.29 | ||
| Q3 24 | — | $1.50 | ||
| Q2 24 | — | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $877.0M | — |
| Total DebtLower is stronger | $4.9B | — |
| Stockholders' EquityBook value | $4.7B | — |
| Total Assets | $13.8B | — |
| Debt / EquityLower = less leverage | 1.03× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $877.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.6B |
| Q1 26 | $4.9B | — | ||
| Q4 25 | $4.7B | — | ||
| Q3 25 | $4.7B | — | ||
| Q2 25 | $5.2B | — | ||
| Q1 25 | $5.2B | — | ||
| Q4 24 | $3.2B | — | ||
| Q3 24 | $3.2B | — | ||
| Q2 24 | $3.5B | — |
| Q1 26 | $4.7B | — | ||
| Q4 25 | $4.6B | $3.3B | ||
| Q3 25 | $4.6B | $5.4B | ||
| Q2 25 | $4.5B | $5.0B | ||
| Q1 25 | $4.7B | $4.7B | ||
| Q4 24 | $4.7B | $4.8B | ||
| Q3 24 | $4.2B | $5.2B | ||
| Q2 24 | $4.0B | $5.0B |
| Q1 26 | $13.8B | — | ||
| Q4 25 | $13.7B | $15.5B | ||
| Q3 25 | $13.6B | $15.2B | ||
| Q2 25 | $13.6B | $14.5B | ||
| Q1 25 | $14.0B | $14.1B | ||
| Q4 24 | $12.9B | $14.2B | ||
| Q3 24 | $12.6B | $14.4B | ||
| Q2 24 | $12.4B | $14.2B |
| Q1 26 | 1.03× | — | ||
| Q4 25 | 1.01× | — | ||
| Q3 25 | 1.02× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.11× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.87× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HSY
Segment breakdown not available.
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
